The Training Component of the Immune Mediated Disorders after Allogeneic HCT Consortium will award a minimum of $50,000 annually to support career development for young investigators with an interest and aptitude for research in this field. Additional funds may be available from institutional resources committed to the PI, and at least one trainee will be supported each year. Trainees will be selected for financial support through an application process that will encourage women and minority candidates to apply. Additional career support will be available through the Consortium including access to data and specimens, participation in ongoing or planned studies, and funds for pilot projects conducted by mid-career investigators interested in reorienting their careers to study rare diseases. Trainees will also have access to training courses locally through the General Clinical Research Centers (GCRC), Clinical and Translational Science Awards (CTSA), Schools of Public Health or other coursework. Several week-long intensive courses supported by professional societies with relevance to the study of immune mediated disorders are also available. Potential mentors at each institution have been identified. Their letters of support and biosketches are provided.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
8U54CA163438-03
Application #
8327078
Study Section
Special Emphasis Panel (ZRG1)
Project Start
Project End
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
3
Fiscal Year
2011
Total Cost
$100,445
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Holtan, Shernan G; DeFor, Todd E; Panoskaltsis-Mortari, Angela et al. (2018) Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. Blood Adv 2:1882-1888
Du, Jing; Flynn, Ryan; Paz, Katelyn et al. (2018) Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients. Blood 131:1743-1754
Hamilton, Betty K; Rybicki, Lisa; Arai, Sally et al. (2018) Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes. Biol Blood Marrow Transplant 24:393-399
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562
Martin, Paul J; Storer, Barry E; Inamoto, Yoshihiro et al. (2017) An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. Blood 130:360-367
Lee, Stephanie J (2017) Classification systems for chronic graft-versus-host disease. Blood 129:30-37
Kariminia, Amina; Holtan, Shernan G; Ivison, Sabine et al. (2016) Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. Blood 127:3082-91
Merkel, Peter A; Manion, Michele; Gopal-Srivastava, Rashmi et al. (2016) The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet J Rare Dis 11:66
Arai, Sally; Pidala, Joseph; Pusic, Iskra et al. (2016) A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. Clin Cancer Res 22:319-27
Arora, Mukta; Cutler, Corey S; Jagasia, Madan H et al. (2016) Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 22:449-55

Showing the most recent 10 out of 46 publications